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CLINICAL INVESTIGATION
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Plasma concentrations and transperitoneal transport of native insulin
and C-peptide in patients on continuous ambulatory peritoneal dialysis.
The insulin and C-peptide response to glucose (50 g), given intraperito-
neally or enterally, and the elimination rate of these compounds has
been studied in five nondiabetic patients on continuous ambulatory
peritoneal dialysis (CAPD). The fasting C-peptide concentrations were
three to ten times the normal values, whereas the fasting plasma insulin
concentrations were within normal limits. After intraperitoneal glucose
administration, a more marked hyperglycemia (P < 0.05) and a more
long lasting hyperinsulinemia (P < 0.05) were found than after the
enteral glucose load. The relative change in plasma C-peptide was
slower and less pronounced in both experiments. Estimated total body
clearance (Kr) for insulin was higher than for C-peptide (P < 0.01), but
dialysis clearance (Kd) for C-peptide was higher than for insulin in both
experiments (P < 0.01). The markedly elevated fasting C-peptide
concentrations in plasma can be explained only partly by the absence of
normal kidney function and suggests a continuously increased produc-
tion of C-peptide during CAPD treatment. This was not reflected by the
fasting plasma insulin concentrations. C-peptide measurements in plas-
ma and dialysate during CAPD could be helpful in evaluating the 13-cell
function in patients in need of exogenous insulin.
Concentrations plasmatiques et transport transpéritoneal de l'insuline
native et du peptide-C chez des malades en dialyse péritonéale continue
ambulatorie. La réponse de l'insuline et du peptide-C a du glucose (50 g)
donnC par voie péritonéale ou parenterale et Ia vitesse d'élimination de
ces substances ont été ëtudiées chez cinq malades non-diabétiques en
dialyse peritonéale continue ambulatoire (CAPD). Les concentrations
de peptide-C a jeün étaient de trois a dix fois les valeurs normales,
tandis que les concentrations d'insuline plasmatique àjeün étaient dans
les limites de Ia normale. Après administration intrapéritonéale de
glucose, une hyperglycemie plus marquee (P < 0,05) et une hyperinsu-
linémie plus prolongée (P < 0,05) qu'aprCs une charge glucosee
parentérale ont ete trouvées. Le changement relatif du peptide-C
plasmatique était plus lent et moms prononcé au cours des deux
experiences. La clearance totale estimCe (Kr) de l'insuline était plus
dlevCe que pour le peptide-C (P < 0,01), mais Ia clearence dialytique
(Kd) du peptide-C était plus élevée que celle de l'insuline dans les deux
experiences (P < 0,01). L'élévation marquee des concentrations de
peptide-C a jeUn dans le plasma ne peuvent qu'être partiellement
expliquees par l'absence de fonction rénale normale, et die suggere une
production augmentée de facon continue du peptide-C pendant le
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traitement par la CAPD. Cela n'était pas reflété par les concentrations
d'insuiine plasmatique ajeUn. Les mesures de peptide-C dans le plasma
et le dialysat en cours de CAPD pourraient être utiles pour évaluer Ia
fonction des cellules-f3 chez des malades ayant besoin d'insuline
exogCne.
Earlier investigations have provided information concerning
the transport of exogeneous insulin from the peritoneal dialy-
sate to plasma [1], but comparable data for transport of the
endogenous hormone and the connecting peptide (C-peptide)
from plasma to dialysate have not been published.
Insulin and C-peptide, which has no recognized metabolic
activity, [2, 3] are produced in the pancreatic /3-cells by
cleavage of proinsulin and subsequently secreted into portal
circulation in equimolar concentrations [4]. The liver removes
about 60 to 70% of the insulin [2, 3], but only minor fractions of
the C-peptide [2, 3]. It has been suggested that C-peptide is
metabolized mainly by the kidney [2]. Normally, 5 to 20% of
pancreatic secretion of C-peptide and 0.1% of endogenous
insulin is excreted in urine [2, 41. Half-time disappearance rates
are about 11 to 33 mm for C-peptide and about 5 mm for insulin
[2, 4, 5]. In the fasting state, the molar concentration of C-
peptide in blood is five to seven times higher than that of insulin
because of the slower turnover of C-peptide. After stimulation,
the relative increase in insulin concentration is higher than for
C-peptide, because of its lower basal concentration [2].
The /3-cell secretory activity can be evaluated by measuring
C-peptide concentrations in plasma and urine, also in insulin-
treated diabetic patients [5, 6]; C-peptide measurements in
plasma and dialysate during CAPD could be of value as an
indicator of the /3-cell function in patients on CAPD-treatment.
Transperitoneal glucose administration would be expected to
give a response similar to intravenous glucose loading, but, to
our knowledge, no data on differences in plasma glucose level
and insulin response between oral and transperitoneal glucose
loads have been published.
The purpose of this study was to investigate the plasma
glucose, insulin, and C-peptide responses to equimolar glucose
loads given either the peritoneal route or the oral route, and the
total elimination and transperitoneal transport of these com-
pounds in patients on CAPD treatment.
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Methods
Patients. Five patients with the mean age of 44 years repre-
senting 21 to 57 years were selected for the investigation after
informed consent was given. Two patients suffered from chron-
ic glomerulonephritis, one from renal amyloidosis secondary to
rheumatoid arthritis, one from juvenile medullary cystic dis-
ease, and one from renal failure due to lecithin-cholesterol
acyltransferase (LCAT) deficiency. One patient was anephric,
the others were anuric or oliguric. All patients had been well
controlled on CAPD treatment for 3 to 16 months. The ex-
change procedure for all patients was four 2-liter bags per day,
that is, three 5-hr shifts during the day and one 9-hr shift during
the night. The mean blood values (± SEM and range) from six to
ten consecutive measurements during this period were: hemo-
globin, 9.5 0.5 gldl (8.2 — 10.8); glucose 5.6 0.2 mmoles/
liter (5.3 — 6.4); albumin, 28 2 g/liter (21 — 33); and
creatinine, 849 88 moles/liter (553 — 1053).
Procedure of investigation
Each patient was examined twice with a 1-week interval.
Experiment 1. A peritoneal glucose infusion of 429 mmoles
(77 g) was given using 2-liters of dialysate containing 3.86 g
glucose/dl (Dianeal®, Travenol Industries, Halden, Norway).
Simultaneous blood and dialysate samples for measurements of
insulin, C-peptide, and glucose concentrations were taken
before the instillation of fluid, and at the subsequent dwelltimes
(Td): 7 (during infusion), 15 (end of infusion), 20, 25, 30, 35, 40,
45, 75, 135, 195, and 255 (end of drainage) mm after the start of
dialysate infusion.
Experiment 2. Anhydrous glucose, 278 mmoles (50 g), dis-
solved in 75 ml water (corresponding to the mean 3 hr transperi-
toneal absorption of glucose during the first investigation, see
Fig. lA) were given by mouth while 1 liter of Ringer lactate
(Knut Spaerens Laboratories A/S, TØnsberg, Norway) was
instilled in the peritoneal cavity. Samples from blood and the
instilled Ringer solution were obtained at the start and then at
the following dwelltimes: 30, 40, 60, 80, 120, and 180 mm
(during drainage). Drained dialysate volumes were measured in
both experiments.
All tests were begun in the morning, and the patients fasted
during each investigation period. During the night before the
test, 2-liters of dialysate containing 1.5 g glucose/dl were
instilled for 9 hr. The peritoneal cavity was drained just before
the investigation began the next morning.
Concentration measurements and kinetic calculations
Glucose concentration was measured using the oxidase meth-
od (Gluc-DH-Method, Merck, Darmstadt, West Germany),
serum creatinine by an autoanalyzer (SMA III, Technicon
Instruments Corporation, Tarrytown, New York), hemoglobin
by a Coulter F analyzer (Coulter Electronics Lim, Harpenden,
United Kingdom) and albumin by determination with bromcre-
sol purple.
C-peptide concentrations were determined by a commercial
RIA-kit ("C-peptide II kit," Aiichi, Tokyo, Japan). The WA-
CV was 4.1% and the BA-CV was 4.3% within the range of 666
to 66600 pmoles/liter. Insulin concentrations were measured by
a commercial RIA-kit ("Phadebas Insulin Test," Pharmacia,
Uppsala, Sweden). The WA-CV 7.1% and the BA-CV was 6.5%
within the range of 73 to 730 pmoles/liter.
As shown by Toffolo et al [7], the calculation of total body
clearance (K1) for insulin and C-peptide was based on a single
compartment model with first order disappearance kinetics
(that is, constant K1), where insulin delivery rate (IDR =
"production") can be simulated as:
IDR = k (Cgh) t if Cg> h, and IDR = 0 when Cg < h (1)
Cg represents glucose concentration in plasma; h, given thresh-
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Fig. 1. Glucose concentrations (C01) in dialysate (A) and instilled Ringer solution (B) and plasma (C) as a function of dwelltime (Td) during
peritoneal (P) and enteral (E) glucose load. Mean SEM from five patients.
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old level of glucose for insulin stimulation; t, time; and k,
individual constant. Values for "K1" were based on Cg < h,
giving IDR = 0, hence
d(CV)
=
— K1 C giving K1 = In () for Cg < h.(2)
C represents the concentration in plasma and T, time. Distri-
bution volume (V) was chosen as 16% of body wt [8].
The calculation of dialysis clearance (Kd) for insulin and C-
peptide must be referred to the plasma concentration of these
compounds, and we chose to use estimated mean plasma values
(Ce) during each of the two experiments as:
= cp . dt t; C = (C+1 + C)/2;
tn = tn+I — tn
which gives a dialytic clearance as:
(Vd Cd — (Vdo Cdo)
Kd - T
For calculation of K, and Kd, 4 hr were used in experiment I
and 3 hr in experiment 2.
Statistical calculations were based on a paired t-distribution
test of the differences between two populations. All values are
given as mean SEM.
Results
The mean (± SEM) drained volume for all patients from the
peritoneal cavity was 2810 49 ml after 4 hr dwelltime during
experiment 1, and 776 47 ml after 3 hr dwelltime during
experiment 2.
Figure 1A, B, and C depicts the relationship between the
glucose concentration in the instilled peritoneal fluids and in
blood as a function of time. Values from enteral (E) and
peritoneal (P) glucose administration for both compartments are
shown. During the first experiment, the measured mean glucose
concentration in the 2 liters of instilled dialysate decreased from
190 8.7 mmoles/liter to 40 4 mmoles/liter after 3 hr. The
ultrafiltration volume was about 0.8 liter, which corresponded
to a mean glucose absorption of 268 mmoles (48 g) (Fig. IA).
The mean glucose loss from plasma to the Ringer solution
during the second experiment was less than 6 mmoles (Fig. 1B).
The maximal increase in blood glucose after enteral ingestion
of 50 g glucose was lower (P < 0.05) than during peritoneal
absorption of glucose. After 3 hr of dwelltime, a slight differ-
ence in blood glucose concentration still existed (P <0.05, Fig.
IC).
In Figure 2 changes in plasma insulin concentration are given
as a percent of the initial fasting values (C%). In both
experiments, plasma insulin increased to about four times the
initial values, but the increase in insulin concentration was
more rapid during enteral than during the peritoneal absorption
of glucose; however, the mean increase during 3 hr (based on
the area under the curve) was about 50% higher after the
peritoneal than after enteral glucose load (P < 0.50). At 3 hr of
dwelltime, the insulin concentration in plasma was still 100%
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Fig. 3. Relative change (in percent of initial value) in plasma C-peptide
concentrations, iC% (C — C)IC0 x 100%, as a function of dwelltime
(Td) during peritoneal (P) and enteral (E) glucose load. Mean SEM
from five patients.
increased after the peritoneal glucose load but normalized after
enteral glucose (P < 0.01).
The relative change (zIC%) in plasma C-peptide concentra-
tions during the two experiments are compared in Figure 3. The
increase in plasma values were slower and reached a level only
about 70% higher than the initial concentration as compared to
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Table 1. Lowest and highest values of insulin and C-peptide concentrations measured in plasma of each patient during peritoneal and anteral
glucose loads
Patient no.
Enteral glucose load Peritoneal glucose load
Insulin
pmoles/liter
C-peptide
pmoleslliter Insulin C-peptide
I
2
3
4
5
49—p 506
67—* 473
656— 1467
100—p 599
90— 796
l665— 3464
2198— 4595
8059— 14119
2930— 4063
3796—4 5528
26— 126
68— 459
274—f 1270
66—f 383
88— 506
2398—p 4262
2364— 4962
949l— 11489
2498—* 4529
2997— 5628
Mean range
SEM
192 116
— 768 184
4330 1020
— 6354 1971
104 44
— 557 191
3950 1390
— 6174 1349
Normal values 0 to 511 376 to 909 — —
400% for insulin (Fig. 2). The disappearance rate for C-peptide
in plasma was also slower than for insulin. No significant
differences between the two experiments were found.
Table I gives the lowest and highest values of insulin and C-
peptide concentrations in plasma for each patient during the
two experiments. The corresponding dwelltimes can be found
by correlating these measured values with the time-dependent
changes of these compounds shown in Figures 2 and 3. The
concentrations of C-peptide were elevated compared to normal
values, while fasting insulin levels were within normal range for
all except one obese women (patient no. 3), who appeared to be
hyperinsulinemic.
In Figure 4 the concentrations in the instilled fluid (Cd)
relative to the mean plasma concentration (Cd, see Methods) for
insulin (4A) and C-peptide (4B) are given as a function of
dwelltime (Td). In both experiments the C-peptide concentra-
tion increased more than the concentration of insulin. During
the peritoneal glucose load, the initial insulin values in the
instillate increased rather irregularly and exceeded those of C-
peptide, but for Td > 45 mm, the increase of both substances
followed a simple diffusional behavior. After 3 hr of instillation
time, the insulin concentration in the instilled fluids was 25.5
8.6% (P) and 26.5 2.3% (E) of mean plasma concentration
(Cr) respectively. The corresponding C-peptide concentrations
were 35.4 3.6% and 50.8 6.8%.
Calculated mean total body clearance (Kr) and dialysis clear-
ance (Kd) for insulin and C-peptide for the two experiments are
shown in Figure 5, and the following differences should be
noted: (1) Estimated K1 for insulin was higher than for C-
peptide (P < 0.01), while Kd for C-peptide was higher than for
insulin (P < 0.01) in both experiments. (2) When changing from
1-liter Ringer solution to 2-liter 4.25% dialysate in the peritoneal
cavity, Kd for insulin increased from 1.13 0.10 to 2.75 0.64
mI/mm (P < 0.05) and for C-peptide from 2.22 0.40 to 4.35
0.40 mI/mm (P < 0.01). K1 for insulin decreased from 208.0
39.8 mL/min during enteral to 117.2 13.2 mI/mm during
peritoneal glucose load (P < 0.025) while K1 for C-peptide was
unchanged in the two experiments, that is, 28.6 6.0 and 28.1
2.7 mI/mm.
Discussion
The relatively rapid and complete absorption of glucose from
duodenum and upper jejunum is due to both energy-dependent
transport against a concentration gradient and diffusive trans-
port [9]. Transperitoneal glucose absorption, however, appears
to be simple diffusive and convective processes dependent only
on individual differences in the peritoneal membrane permeabil-
ity and the concentration gradient [I]. Peritoneal absorption
takes longer time than intestinal absorption. To absorb a dose of
50 g glucose from an intraperitoneal pool of about 70 g (mea-
sured value) in 2 liters, 3 hr of dwelltime were needed (Fig. 1).
The individual variability in absorption following this route of
administration was about 30%. A more pronounced initial and
longer lasting hyperglycemia was found when glucose was
given through the peritoneal membrane (Fig. 1), and after 1 hr
all patients remained more hyperinsulinemic during the perito-
neal glucose load (Fig. 2).
The lasting hyperglycemia and hyperinsulinemia after perito-
neal glucose administration can be explained by the slow and
continuous absorption of glucose together with peripheral car-
bohydrate intolerance in uremic patients [10, Il]. The different
initial hyperglycemia (0 to 45 mm) in the two experiments can
be due to differences in both glucose absorption and transport
to peripheral blood. However, it is difficult to depict differences
in these mechanisms. More than 60% of orally ingested, highly
concentrated glucose solutions is absorbed within the first
minutes [9, 12]. After intraperitoneal glucose administration,
the glucose concentration decreased from about 190 to 110
mmoles/liter after 45 mm. If the ultrafiltration volume at 45 mm
of dwelltime is estimated to be about 500 ml 11], calculated
glucose absorption is 19 g. These findings, which agree with
earlier measurements [1] contrast with the higher blood glucose
levels found during peritoneal load in this study.
An explanation of the different degree of initial hyperglyce-
mia in these experiments could be that a larger part of peritone-
ally absorbed glucose bypasses the portal circulation than does
glucose absorbed from the intestine. It is uncertain from this
study if the insulinotropic properties of gastric hormones [13]
are of any importance in this matter.
The time-dependent relative changes in plasma C-peptide
concentrations were slower and less pronounced than for
insulin (Figs. 2 and 3). After stimulation, the C-peptide concen-
tration in plasma was increased by 70% as compared to 400%
for insulin. This is caused by the higher basal concentration of
C-peptide [2], as the absolute increase in C-peptide values
(pmoles/liter) (Table 1) was higher than that of insulin. The
higher fasting values and slower disappearance rate for C-
peptide are consistent with the lower hepatic and peripheral
degradation rate found for C-peptide as compared to insulin [2,
31.
Increased fasting plasma C-peptide concentration in patients
with chronic renal diseases have been reported by other investi-
gators [14]. It was assumed that this elevation was attributed
mainly to the failure of the diseased kidney either to degrade C-
peptide or to excrete it into the urine, and to the state of uremia
resulting in increased production of C-peptide. Increased molar
ratio between fasting plasma C-peptide and insulin in uremic
patients is also reported [14]. Our study confirms these findings;
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however, both the fasting concentrations in plasma of C-peptide
and the ratio between C-peptide and insulin were much higher
than those found by other investigators in uremic patients
treated with hemodialysis [14]. This could indicate that CAPD
treatment results in a continuously increased production of
proinsulin. This assumption could not be reflected by measure-
ment of fasting insulin concentrations which were within the
normal range.
After 4 hr of instillation of 2-liter hypertonic dialysate, the
concentration in the instilled fluid relative to their mean plasma
values, was about 25% and 39% for insulin and C-peptide,
respectively (Fig. 4). These values are also reflected in the
significantly higher Kd for C-peptide than for insulin (Fig. 5) and
is probably due to the different molecular weights of insulin
(—6000 daltons) and C-peptide (—3000 daltons). As expected
from simple diffusion and convection, increased dialysate vol-
ume and osmolality resulted in increased Kd for both hormones
(Fig. 5). Consistent with previous findings in diabetic and
nondiabetic patients with normal renal function [2, 5, 6, 8], we
found a significantly higher K for insulin than for C-peptide,
reflecting the higher metabolic clearance [2, 3]. The lower K
for insulin during the peritoneal glucose load compared to the
enteral glucose load can be explained by the model used for
calculation of K. Continuous glucose absorption through the
peritoneum gives a sustained insulin secretion which causes the
calculated clearance for insulin during peritoneal glucose ad-
ministration to be underestimated as the formula used does not
assume insulin production. The value for dialytic clearance of
endogenous insulin was slightly higher than that previously
found for ('251)-labelled insulin administered into the peritoneal
cavity (2.3 mI/mm) [1], and these small differences have previ-
ously been explained to be caused by convective effects [15].
In conclusion, measurements of the time-dependent changes
in plasma C-peptide concentrations after stimulation were not
so sensitive as that of plasma insulin concentrations, but the
three to ten times increased fasting C-peptide values in plasma
assumes a continuous increased production of proinsulin during
CAPD treatment. C-peptide concentrations in samples from
instilled dialysate give a better estimate of plasma levels than
corresponding insulin values. Measurements of C-peptide in
both plasma and in the instilled peritoneal dialysate could be of
value for an evaluation of /3-cell function in patients on CAPD
treatment needing exogeneous insulin and producing antibodies
to this exogeneous compound.
Our experiments also show that the peritoneal route results in
more prolonged hyperglycemia and hyperinsulinemia than the
enteral. As insulin augments the hepatic production of triglycer-
ides and very low density lipoproteins [16], this may contribute
to a higher risk of progressive atherosclerosis in patients treated
with CAPD. Substantiation of this is found in the preliminary
findings of higher triglyceride levels in nondiabetic than in
diabetic patients on CAPD treatment [17]. Long-term observa-
tions on changes in insulin response during CAPD treatment are
still lacking.
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